EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

EMA paediatric investigation plans in-person training course, European Medicines Agency, Amsterdam, the Netherlands, from 5 November 2026, 08:00 (CET) to 6 November 2026, 16:30 (CET)

Human medicines European public assessment report (EPAR): Cabometyx, cabozantinib, Date of authorisation: 09/09/2016, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Nexviadyme, avalglucosidase alfa, Date of authorisation: 24/06/2022, Revision: 7, Status: Authorised

Draft reflection paper on the investigation of drug interactions of herbal medicinal products

Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised

Academia

Opinion/decision on a Paediatric investigation plan (PIP): Opdualag, nivolumab,relatlimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0169/2024

Human medicines European public assessment report (EPAR): Dovprela (previously Pretomanid FGK), pretomanid, Date of authorisation: 31/07/2020, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 7, Status: Authorised